Johnson & Johnson Price to Sales Ratio 2010-2022 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of January 27, 2023 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2023-01-27 |
168.23 |
|
4.72 |
| 2022-12-31 |
176.65 |
$35.67 |
4.95 |
| 2022-09-30 |
162.32 |
$36.00 |
4.51 |
| 2022-06-30 |
175.20 |
$35.79 |
4.90 |
| 2022-03-31 |
173.83 |
$35.51 |
4.89 |
| 2021-12-31 |
166.70 |
$35.14 |
4.74 |
| 2021-09-30 |
156.34 |
$33.76 |
4.63 |
| 2021-06-30 |
158.53 |
$31.92 |
4.97 |
| 2020-12-31 |
149.58 |
$30.94 |
4.83 |
| 2020-09-30 |
140.51 |
$30.25 |
4.64 |
| 2020-06-30 |
131.85 |
$30.12 |
4.38 |
| 2020-03-31 |
122.09 |
$30.88 |
3.95 |
| 2019-12-31 |
134.94 |
$30.55 |
4.42 |
| 2019-09-30 |
118.86 |
$30.30 |
3.92 |
| 2019-06-30 |
127.95 |
$29.99 |
4.27 |
| 2019-03-31 |
127.55 |
$30.01 |
4.25 |
| 2018-12-31 |
116.98 |
$29.91 |
3.91 |
| 2018-09-30 |
124.45 |
$29.79 |
4.18 |
| 2018-06-30 |
108.57 |
$29.51 |
3.68 |
| 2018-03-31 |
113.82 |
$28.73 |
3.96 |
| 2017-12-31 |
123.31 |
$27.86 |
4.43 |
| 2017-09-30 |
114.05 |
$26.99 |
4.23 |
| 2017-06-30 |
115.31 |
$26.21 |
4.40 |
| 2017-03-31 |
107.85 |
$25.95 |
4.16 |
| 2016-12-31 |
99.12 |
$25.74 |
3.85 |
| 2016-09-30 |
100.93 |
$25.58 |
3.95 |
| 2016-06-30 |
102.95 |
$27.53 |
3.74 |
| 2016-03-31 |
91.19 |
$27.01 |
3.38 |
| 2015-12-31 |
85.95 |
$27.10 |
3.17 |
| 2021-03-31 |
157.18 |
$26.92 |
5.84 |
| 2015-09-30 |
77.54 |
$24.94 |
3.11 |
| 2015-06-30 |
80.33 |
$25.29 |
3.18 |
| 2015-03-31 |
82.31 |
$25.75 |
3.20 |
| 2014-12-31 |
84.97 |
$25.91 |
3.28 |
| 2014-09-30 |
86.05 |
$25.91 |
3.32 |
| 2014-06-30 |
83.89 |
$25.56 |
3.28 |
| 2014-03-31 |
78.22 |
$24.96 |
3.13 |
| 2013-12-31 |
72.41 |
$24.78 |
2.92 |
| 2013-09-30 |
68.07 |
$24.65 |
2.76 |
| 2013-06-30 |
66.92 |
$24.60 |
2.72 |
| 2013-03-31 |
63.06 |
$24.30 |
2.59 |
| 2012-12-31 |
53.79 |
$24.00 |
2.24 |
| 2012-09-30 |
52.42 |
$23.61 |
2.22 |
| 2012-06-30 |
50.93 |
$23.32 |
2.18 |
| 2012-03-31 |
49.25 |
$23.40 |
2.10 |
| 2011-12-31 |
48.54 |
$23.42 |
2.07 |
| 2011-09-30 |
46.70 |
$23.17 |
2.02 |
| 2011-06-30 |
48.35 |
$22.79 |
2.12 |
| 2011-03-31 |
42.70 |
$22.30 |
1.91 |
| 2010-12-31 |
44.17 |
$22.06 |
2.00 |
| 2010-09-30 |
43.87 |
$22.38 |
1.96 |
| 2010-06-30 |
41.43 |
$22.40 |
1.85 |
| 2010-03-31 |
45.32 |
$22.40 |
2.02 |
| 2009-12-31 |
44.43 |
$22.20 |
2.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$441.560B |
$94.943B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
